- Home
- CSAN vs IMCR Comparison
CSAN vs IMCR Comparison
Compare CSAN & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSAN
- IMCR
- Stock Information
- Founded
- CSAN 1936
- IMCR 2008
- Country
- CSAN Brazil
- IMCR United Kingdom
- Employees
- CSAN N/A
- IMCR N/A
- Industry
- CSAN Retail-Auto Dealers and Gas Stations
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CSAN Consumer Discretionary
- IMCR Health Care
- Exchange
- CSAN Nasdaq
- IMCR Nasdaq
- Market Cap
- CSAN 2.1B
- IMCR 1.7B
- IPO Year
- CSAN N/A
- IMCR 2021
- Fundamental
- Price
- CSAN $4.41
- IMCR $33.35
- Analyst Decision
- CSAN Hold
- IMCR Buy
- Analyst Count
- CSAN 3
- IMCR 8
- Target Price
- CSAN $9.47
- IMCR $57.00
- AVG Volume (30 Days)
- CSAN 1.5M
- IMCR 334.0K
- Earning Date
- CSAN 11-12-2025
- IMCR 11-05-2025
- Dividend Yield
- CSAN N/A
- IMCR N/A
- EPS Growth
- CSAN N/A
- IMCR N/A
- EPS
- CSAN N/A
- IMCR N/A
- Revenue
- CSAN $7,993,490,490.00
- IMCR $356,145,000.00
- Revenue This Year
- CSAN $270.07
- IMCR $29.71
- Revenue Next Year
- CSAN $1.31
- IMCR $11.27
- P/E Ratio
- CSAN N/A
- IMCR N/A
- Revenue Growth
- CSAN 7.98
- IMCR 26.78
- 52 Week Low
- CSAN $3.80
- IMCR $23.15
- 52 Week High
- CSAN $8.64
- IMCR $39.33
- Technical
- Relative Strength Index (RSI)
- CSAN 45.22
- IMCR 47.52
- Support Level
- CSAN $4.28
- IMCR $33.04
- Resistance Level
- CSAN $4.50
- IMCR $34.11
- Average True Range (ATR)
- CSAN 0.15
- IMCR 1.21
- MACD
- CSAN 0.01
- IMCR -0.03
- Stochastic Oscillator
- CSAN 60.67
- IMCR 50.63
About CSAN Cosan S.A. ADS
Cosan SA engages in several services throughout the energy and logistics sectors. Its reportable segments are Raizen, Compass, Moove, Rumo, and Radar. It generates the majority of its revenue from Raizen which operates in the production, commercialization, origination, and trading of ethanol, bioenergy, resale, and trading of electricity, renewable sources, marketing, origination, and trading of sugar and fuels, and lubricant.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.